What is Sanguine Biosciences?
Headquartered in Sherman Oaks, California, Sanguine Biosciences operates at the intersection of mobile technology and clinical research. The company provides a sophisticated platform that facilitates the collection of biological specimens, effectively streamlining the process for pharmaceutical and biotech companies to conduct clinical trials. By prioritizing patient convenience and data integrity, Sanguine has carved out a distinct niche in the healthcare landscape, enabling more efficient drug development and personalized medicine initiatives.
The company's business model is built upon the premise that patient participation is the primary bottleneck in medical innovation. By leveraging mobile technology to bring research opportunities directly to the patient, Sanguine not only improves the quality of data collected but also enhances the overall patient experience. This operational focus has made them a critical partner for organizations seeking to accelerate their research pipelines while maintaining rigorous clinical standards.
How much funding has Sanguine Biosciences raised?
Sanguine Biosciences has raised a total of $21.7M across 5 funding rounds:
Other Financing Round
$2M
Private Equity
$5.5M
Series A
$4M
Debt
$150K
Debt
$10M
Other Financing Round (2013): $2M with participation from Seraph Group, Heliant Ventures, Invent Ventures, and Mayo Clinic
Private Equity (2014): $5.5M, investors not publicly disclosed
Series A (2014): $4M supported by Seraph Group
Debt (2020): $150K featuring PPP
Debt (2023): $10M backed by Catalio Capital Management
Key Investors in Sanguine Biosciences
Catalio Capital Management
A New York-based investment firm specializing in innovative healthcare investing across private, public, and credit markets, with a focus on breakthrough biomedical technology.
Mayo Clinic
A nonprofit global healthcare organization renowned for its integrated clinical practice, medical research, and commitment to healthcare innovation.
Seraph Group
A venture capital firm that provides strategic backing to early-stage and growth-oriented technology companies, focusing on scalable business models.
What's next for Sanguine Biosciences?
With the recent influx of capital, Sanguine Biosciences is well-positioned to expand its technological infrastructure and broaden its reach within the clinical research ecosystem. The company is expected to leverage these funds to enhance its specimen collection capabilities and potentially enter new therapeutic areas that require specialized patient engagement. As the demand for decentralized clinical trials continues to rise, Sanguine's platform is poised to become an industry standard for researchers seeking reliable, high-quality biological data.
Strategic priorities likely include the integration of advanced analytics to further optimize the specimen collection workflow and the expansion of its network of clinical partners. By maintaining its focus on patient-centric innovation, Sanguine is set to play a pivotal role in the future of biomedical research, ensuring that the next generation of medical breakthroughs is supported by robust, accessible, and ethically sourced clinical data.
